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Summary Proliferating cell nuclear antigen (PCNA) is a nuclear protein that regulates DNA synthesis by
DNA polymerase delta, and is essential for DNA replication. PCNA expression level is related to the
malignancy of gastric cancer cells. Seven different gastric cancer cell lines and two kinds of control cell lines
were treated with antisense oligonucleotides complementary to the messenger RNA of PCNA. Treatment of
each gastric cancer cell line with antisense oligonucleotides at concentration of 10-40IM inhibited the cell
growth, colony formation and PCNA protein production in a dose-dependent manner, but only affected
normal cells slightly. A random sequence oligomer showed no effect. These results show that PCNA is
essential for gastric cancer cell proliferation and that the use ofsynthetic oligonucleotides is an effective way of
producing antisense-mediated changes in the behaviour of human gastric cancers.
Gastric cancer is morphologically and functionally pleomor-
phic (Mulligan & Rember, 1958; Ming, 1977), and it has
been suggested that many kinds of growth factors and their
receptors form multiautocrine loops that regulate cancer cell
growth and development (Yoshida et al., 1989). Expression
of epidermal growth factor (EGF), transforming growth fac-
tor a (TGF-c), EGF receptor and PCNA is apparently
involved in the malignancy of gastric cancer cells (Yasui et
al., 1988; Yoshida et al., 1990; Yonemura et al., 1993).
Recent investigations have shown that oncogenes encode
growth factors, their receptors and other parts of the signal
transduction mechanisms, all of which play important roles
in controlling the growth of cancerous and normal cells
(Sporn & Roberts, 1985). The signal transduction mechanisms
often involve a final common pathway that is shared by
diverse growth signals. The convergence to a common path-
way is illustrated by a nuclear protein, proliferating cell
nuclear antigen (PCNA), which is critical for DNA replica-
tion. PCNA is a nuclear protein required for regulating DNA
synthesis by DNA polymerase delta, which plays an essential
role in DNA replication (Julio & Celis, 1985; Bravo et al.,
1987). PCNA constitutes an important factor in this process;
it is a cofactor for DNA polymerase delta, and both the
cofactor and the enzyme are required for coordinated leading
and lagging strand replication of DNA.
One of the general approaches previously explored for the
treatment of cancer was the development of interventions
that inhibit specific factors involved in the signal transduc-
tion pathways leading to cell division (Masui et al., 1984;
Aboud-Pirak et al., 1989; Masui et al., 1989). Nonetheless, if
one such pathway is inhibited, other pathways might still
produce substantial cell proliferation. Consequently, to
effectively suppress cell proliferation the intracellular factors
that are involved in a final common pathway, shared by
mitogenic signals, should be targeted. PCNA is one of the
intracellular factors that is common to all pathways of DNA
synthesis.
Since gastric cancers with high PCNA expression show a
more malignant clinical course than those with low PCNA
expression (Yonemura et al., 1993), it follows that inhibition
of PCNA expression in gastric cancer cells should reduce
their malignancy and improve the clinical course. The present
study was performed to determine whether antisense oligo-
nucleotides complementary to the messenger RNA (mRNA)
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of PCNA would inhibit PCNA expression and thereby in-
hibit the proliferation of gastric cancer cells. If proliferation
of gastric cancer cells could be inhibited by antisense
oligonucleotides specific to PCNA mRNA, their application
might be a useful chemotherapeutic strategy for treating
cancer.
Materials and methods
Cell culture
The human gastric cancer cell lines MKN1, MKN28,
MKN45, MKN74, NUGC-2 and NUGC-3 were cultured in
RPMI-1640 (Nissui, Tokyo) with 10% fetal bovine serum
(FBS) and 100 IU of penicillin at 37°C under standard condi-
tions.
The human myelomonocytic cell line WEHI-3 and human
fibroblast FL cells were cultured in the same conditions and
used as control cells. Another gastric cancer cell line, KATO-
III, was cultured in Dulbecco's modified Eagle medium
supplemented with 10% FBS.
Oligonucleotide synthesis
Eighteen-base oligonucleotides were synthesised using the
Applied Biosystems 380B DNA synthesiser (Applied Bio-
systems, Foster City, CA, USA) with a phosphorothioate
substitution at each base. The oligomers were purified by two
different high-performance liquid chromatography (HPLC)
methods (Murakami et al., 1993), and purity was assayed by
polyacrylamide gel electrophoresis and HPLC. The antisense
oligonucleotides were complementary to 18-bp sequences
next to the start codon or overlapping the start codon of
PCNA mRNA sequences, as shown in Figure 1. Sterile ali-
quots of 1 mM stock solutions were stored at -20°C and
thawed on ice before use.
Oligonucleotide uptake
Random sequence phosphorothioate oligonucleotides were
conjugated with fluorescein 5-isothiocyanate (Fluorescein-ON
Phosphoramidite; Clontech, Palo Alto, CA, USA) according
to the procedure of Wachter et al. (1986). Cells were seeded
at a density of 5 x I03 ml-' in 60 mm tissue culture dishes.
After 24 h, the media were changed, and three 10 mm glass
cloning cylinders were plated on each plate. The labelled
oligonucleotides were then added at a concentration of 5tM
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to the medium within the cloning cylinders. Plates were
harvested at 30 min, 1 h and then hourly. The cells were
washed several times in cold phosphate buffer (PBS), and
fixed for 5 min in 10% formaldehyde. After fixation, the
plates were washed again with PBS, and coverslips were
mounted using Vectashield (Vector Laboratories, Burlin-
game, CA, USA). Cultures were viewed and photographed
immediately under a UV fluorescent microscope.
Growth rate
Cells were plated at a density of 1 x I04cells ml' into 24-
well dishes for 24 h. The medium was then changed to one
AUG site
*1,430
1. 5'-GCCACCAUG G-3'*
2.
3.
* 1,424 1,441
5'-GCC UGGUCCAG-3' **
* 1,421 *1,438
5'- _CGCCUGGUCCAG-3'
**
Figure 1 The sequences of PCNA mRNA targeted by the anti-
sense oligonucleotides. Three targeted sequences are boxed with
corresponding nucleotide number from sequences ofTravali et al.
(1989). The start codon of the gene is underlined. The inhibitory
potency of the antisense oligonucleotides was related to the small
shift in the sequence targeted. Inhibits gastric cancer cell pro-
liferation; "No effect.
containing 10% FBS and various concentrations (10, 20 or
40 M) of either antisense oligomer, scrambled oligomer or
PBS were added. Daily, the cells were digested with trypsin
and counted. Each test was performed in triplicate and
repeated at least three times for each concentration of oligo-
nucleotides. The growth medium, with or without oligonu-
cleotides was changed daily.
Anchorage independence
Anchorage independence was assayed by seeding cells in
0.3% SeaKem low melting point agarose (FMC Bioproducts,
Rockland, ME, USA) dissolved in 2 x RPMI media with or
without oligonucleotides. Suspensions, containing 50 or
500 cells ml-', were overlaid on a 0.6% agarose basal layer in
60 mm culture dishes and incubated at 37°C for 14-21 days.
Foci containing more than 100 cells counted.
Immunohistochemical detection ofPCNA
Cells were seeded at 5,000 cm-2 in four-well chamber slides
for 24 h culture, new medium containing 10% FBS and
either 20tLM antisense or scrambled oligonucleotides was
added and the slides were incubated for 48 h. The cells were
rinsed with PBS and the percentage PCNA expression was
detected using the avidin-biotin peroxidase complex method
(Furth et al., 1987) with the VECTASTAIN ABC kit (Vector
Laboratory, Burlingame CA, USA). All subsequent proce-
dures were performed at room temperature. Non-specific
binding sites were blocked with 10% normal horse serum for
30 min. The serum was removed and the cells were then
incubated with 10tiM monoclonal anti-PCNA antibody
(Dako-PCNA, PC1O Glostrup, Denmark) for 1 h. After rins-
ing with PBS for 15 min, the slides were incubated with
peroxidase-conjugated goat anti-mouse IgG + IgM (Jackson
a b
C d
Figure 2 Uptake of random sequence oligonucleotides in MKN 74 cells, as seen by UV fluorescence microscopy. Fluoresceinated
oligonucleotides were added to the culture, which was then photographed at x 400 after 30 min (a), 1 h (b), 2 h (c) and 4 h
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ImmunoResearch Laboratory, PA, USA) for 30 min. Fc
ing a 15 min PBS rinse, the cells were incubated for 34
with avidin DH-biotinylated horseradish peroxidase H
plex (ABC). The slides were rinsed for Omin and re
with diaminobenzidine in 0.01% hydrogen peroxide sol
for 5 min. After a final PBS rinse the samples were cou
stained with haematoxylin, dehydrated in ethanol, clear
xylene and mounted under coverslips using Permount.
Western blot analysis
Cells were cultured in complete medium containing I
oligonucleotides for 48 h. Cells were trypsinised, flash-f
in liquid nitrogen and incubated in lysis buffer [0
Tris-HCI (pH 7.5), 0.144M sodium chloride, 0.5% N
0.5% SDS and 0.1% aprotinin (1 x 106cells per 20
buffer)] for 30 min on ice and then vortexed. The lysates
centrifuged at 10,000 g for 0 min and subjected to 6-
SDS-PAGE at 20 mA for 2.5 h. Each well was loaded
approximately 20 1 (1I00 Lg of protein) of the samples
proteins were transferred for 90 min at 100 V in a Pol
(American Bionetics, Hayward, CA, USA). Immunoblo
performed using anti-PCNA monoclonal antibody at dil
of 1:1,000, and then with peroxidase-conjugated secor
antibody at a dilution of 1:5,000.
Statistical analysis
Differences in inhibition of cell growth and colony form
were evaluated with Student's t-test.
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Results
Oligonucleotide uptake
Fluorescence microscopy revealed that all cells were capable
of taking up the oligonucleotides. After 30 min of exposure,
faint fluorescence was seen on the outer membrane, and by
1 h about 80% of the cells showed diffuse cytoplasmic stain-
ing. Within 2 h, up to 70% of the cells showed very intense
nuclear staining. By 4 h, the nuclear fluorescence had disap-
peared to be replaced by a coarse granular staining of the
cytoplasm, and therefore no fluorescence was detectable. All
cell types showed a similar time course and pattern of stain-
ing (Figure 2).
Growth rate
-w2%r When plated at an initial density of 1 x I04cells ml-', all cell
with lines grew to maximum density within 6 days. At all times
The examined the growth of all gastric cancer cell lines was iyothe inhibited by the presence of the antisense oligonucleotides, lyblot but to a lesser degree in FL cells and WEHI-3 cells. Random
ution sequence oligonucleotides showed no effect on the growth of
ndary any cell lines. The growth inhibition of MKN28, MKN74 Y and KATO-III cells is shown in Figure 3. The other gastric
cancer cells showed similar results. Treatment with 10-40tAM
antisense oligonucleotides inhibited the growth of gastric
cancer cells in a dose-dependent manner, but each oligomer
ation showed only a slight effect on the proliferation of FL cells and WEHI-3 cells (Figures 3 and 4).
When the composition of the antisense oligonucleotides
was altered to make them complementary to a slightly 3'
b region that spanned the start codon, significant differences
were observed in the growth-inhibitory effect. The inhibitory
effect of three kinds of antisense oligonucleotides against
MKN28, MKN45, MKN74 and KATO-III cells was com-
pared. Antisense oligonucleotides starting at base 1,447
showed growth inhibition of each cell line, but the other two
antisense oligonucleotides starting at base 1441 or starting at
base 1,438 did not show inhibition of cell proliferation (Table
I).
Anchorage independence
The ability to form foci in soft agar was reduced by antisense
oligonucleotide treatment in each gastric cancer cell line
(Table II).
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Figure 3 Growth curves of gastric cancer cells and control cells.
MKN 28 (a), MKN 74 (b), KATO-I1I (c) and FL (d) cells were
incubated with 20 tM antisense (A) or sense (0) oligonucleotides
or phosphate-buffered saline (-). Cells were seeded in growth
medium on day 0, and incubated for 24 h. The cells were then
incubated with 20 JLM antisense or sense oligonucleotides or
phosphate-buffered saline in fresh medium. Medium containing
oligonucleotides was changed daily. The experiments were repeat-
ed three times. Results represent mean ± standard deviation from
triplicate cultures. The difference between antisense-treated and
control curves was statistically significant with Student's t-test
(P<0.0I).
Effect ofPCNA-specific antisense oligonucleotides on protein
expression: immunohistochemical analysis
In growing gastric cancer cells without treatment or treated
with 20pr M scrambled oligonucleotides for 48 h, most nuclei
were stained with similar high intensities. In contrast, more
than 70% of gastric cancer cells treated with 20tAM antisense
oligonucleotides for 48 h showed weakly stained nuclei.
Figure Sa and b show untreated MKN28 and MKN74 cells,
Figure Sc and d MKN28 and MKN74 cells treated with
PCNA-specific antisense oligomer and Figure Se and f
MKN28 and MKN74 cells exposed to scrambled oligo-
nucleotides. The results presented in Figure 5c and d show
that exposure to antisense oligomers reduced the absolute cell
number and the number of cells displaying intranuclear
immunoreactive PCNA antigen in each cell line. Other cell
lines showed similar results.
Effect ofPCNA-specific antisense oligonucleotides on protein
expression: Western blots
Immunoblots demonstrated a marked decrease in the level of
PCNA protein after incubation in antisense oligomer, where-
as no decrease was apparent in the cells exposed to scrambled
oligonucleotides or PBS in each kind of gastric cancer cells
(Figure 6a-g). The PCNA protein level in normal cells, FL
cells and WEHI-3 cells also decreased slightly (Figure 6h and
i).
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Figure 4 Concentration dependence of cell growth by the antisense oligonucleotides. Percentage inhibition was calculated on day 6
using the number of cells present in the control cultures incubated with PBS for comparison. Each point represents the
mean ± standard deviation of triplicate cultures. The experiments were repeated three times with similar results. The difference
between antisense-treated (open bars) and scrambled oligonucleotides-treated (shaded bars, control) groups was statistically
significant in all cell lines with Student's t-test (P<0.005-0.01).
Table I The inhibitory potency of the antisense oligonucleotides in
gastric cancer cell proliferation and its relation to a small shift in the
targeted sequence of PCNA mRNA
First base of
antisense
oligonucleotides'
Inhibition of cell growth (%)
KATO-III MKN 28 MKN 45 MKN 74
1,447 (antisense 1) 81.1±8.3 86.7±5.9 74.2±4.6 95.7±6.8
1,441 (antisense 2) 13.7 ± 4.2 9.2 ± 3.4 7.3 ± 4.8 9.4 ± 3.3
1,438 (antisense 3) 5.8 ± 3.7 6.4 ±4.9 11.9± 5.6 4.9 ± 3.6
aNumbering is from the sequences of Travali et al. (1989) as shown
in Figure 1. Gastric cancer cell lines MKN 28, MKN 45, MKN 74
and KATO-III cells were incubated with three kinds of 20 IM
antisense oligonucleotides or PBS after serum starvation. Medium
containing oligonucleotides was changed daily. After incubation for
72 h cell number was counted and per cent inhibition of cell growth
was calculated in comparison with non-treated cells. Results
represent mean ± standard deviation from triplcate cultures. The
difference in growth inhibition between antisense 1-treated and
antisense2- or 3-treated cell growth was statistically significant
(P< 0.005).
Discussion
We have previously performed chemotherapy against gastric
cancer with many kinds of drug delivery systems and have
obtained good results (Hagiwara et al., 1992, 1993). How-
ever, in some cases the anti-cancer agents were ineffective,
probably because of multidrug resistance or low concentra-
tion of drugs in the cancerous lesion. In this report we used
antisense oligonucleotides and focused on PCNA as a target
for the treatment of gastric cancer. The fact that expression
of multiple cell mitogens and receptors, such as EGF, TGF-
a, and EGF receptors, is detected in gastric cancer cells
Table II Effects of oligonucleotides on focus formation by gastric
cancer cells in soft agar
Foci
Antisense Scramble Control
Cell line (20gM) (20pM) (PBS)
MKN 1 28.2 3.6 54.0 2.9 57.6 3.3
MKN 28 62.8 8.2 134.1 ±9.8 149.4 4.3
MKN 45 30.3 ± 6.2 65.3 ± 3.6 80.7 + 3.3
MKN 74 52.7± 10.2 134.6± 11.2 123.3 10.6
KATO-III 28.3 + 4.6 42.7 ± 6.5 46.2 + 5.8
NUGC-2 20.3 ± 8.3 50.1 ± 6.9 55.1 ± 9.7
NUGC-3 16.9 ± 3.8 38.5 ± 5.1 39.9 ± 5.9
Cells were seeded at 50 or 500 cellsml-' into culture medium
containing 0.3% agarose in the presence or absence of
oligonucleotides. Suspensions were pipetted onto a basal layer of
0.6% agarose in 60mm dishes and incubated for 14-21 days. Foci
containing greater than 100 cells were counted. Results represent the
mean±standard deviation for triplicate cultures.
suggests that these multiple pathways must converge at the
G,//S boundary and share a common mechanism that causes
DNA replication. PCNA is one of the critical factors in this
convergence.
PCNA is a nuclear protein required for regulating DNA
synthesis by DNA polymerase delta, and forms a part of an
essential pathway for DNA replication in normal cells as well
as malignant cells. PCNA expression in gastric cancer cells is
related to their proliferative activity, malignancy and malig-
nant clinical course (Yonemura et al., 1993). This protein
undoubtedly plays an important role in gastric cancer pro-
liferation and advancement. From these observations we
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Figure 5 lmmunohistochemical detection of PCNA expression in cells treated with antisense or scrambled oligonucleotides
(original magnification x 200). Each cell was treated with antisense or scrambled oligonucleotides for 48 h and PCNA protein
expression was examined with the ABC method. a and b, Untreated MKN 28 and MKN 74 cells. c and d, MKN 28 and MKN 74
cells treated with PCNA-specific antisense oligonucleotides. e and f, MKN 28 and MKN 74 cells treated with scrambled
oligonucleotides. c and d show that exposure to oligomer reduced the absolute cell number and the number of cells displaying
intracellular immunoreactive PCNA antigen in each cell line.
hypothesised that down-regulation of PCNA expression with
antisense oligonucleotides should be useful in the treatment
of gastric cancers.
Antisense oligomers have sequences that are complemen-
tary to the mRNA sequences of the target gene, and their use
frequently leads to modifications in the proliferation and the
phenotype of cells. Many cell lines take up oligonucleotides
immediately, and transfer them to the nucleus (Iverson et al.,
1992; Hawley & Gibson, 1992). Genes such as bcr-abl that
are expressed only in chronic myelocytic leukaemia cells with
a 9;22 chromosomal translocation or the human papilloma-
virus (HPV) associated with oral and cervical cancers are
logical targets for antisense oligonucleotides (Szcyzlik et al.,
1991; Steel et al., 1993). But since such specific genes have
not been found yet in gastric cancer cells, we targeted PCNA
mRNA which is abundantly expressed in gastric cancer cells
with high proliferative activity.
Expression of PCNA is very weak in quiescent cells, but
increases 6- to 7-fold after stimulation by serum, platelet-
derived growth factor (PDGF), fibroblast growth factor
(FGF) or EGF (Bravo & Macdonald-Bravo, 1984; Jaskulsky
et al., 1988a,b). The level of PCNA correlates directly with
the rate of cellular proliferation and DNA synthesis. An
earlier report showed that PCNA antisense oligonucleotides
targeted for mRNA of murine 3T3 cells and rodent smooth
muscle cells inhibited DNA synthesis (Jaskulsky et al.,
1988a,b; Edith Speir et al., 1992). Jaskulsky et al. (1988a,b)
showed the growth-inhibitory effect of PCNA antisense oligo-
nucleotides against murine 3T3 cells with the labelling index
and mitotic index after the incorporation of [3H]thymidine.
This result coincides with our results in FL cells.
The results of our investigations indicate that PCNA is
essential for the proliferation ofgastric cancer cells. Although
it is possible that an antisense strategy might ultimately be
used in vivo to inhibit the proliferation of gastric cancer cells
as one anti-cancer agent, several problems needed to be
solved. Despite the fact that oligonucleotides are avidly taken
up into cells, nuclear and cytoplasmic staining with FITC-
a
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Figure 6 Western blot of oligonucleotide-treated gastric cancer
cells. a, MKN I; b, MKN 28; c, MKN 45; d, MKN 74;; e,
KATO-III; f, NUGC-2; g, NUGC-3; b, FL; i, WEHI-3; Lane 1,
scrambled (20gLM); lane 2, antisense (20 LM); lane 3, PBS. Cells
(1 x 106) were treated with antisense or scrambled oligonucleo-
tides or PBS for 48 h. One hundred micrograms of total protein
was loaded in each lane.
labelled oligonucleotides was weak in some cells of each cell
line used in our experiments. Steel et al. (1993) reported that
up to 75% of the cells took up oligonucleotides, and in our
studies cytoplasmic staining was apparent in about 80% of
the cells and 70% of them had nuclear staining. Thus, since
some cells have an apparent lower affinity for oligomer
uptake, high concentrations of the oligonucleotides would be
necessary to maximally reduce PCNA protein synthesis.
Nonetheless, some cells could escape the antiproliferative
effects of antisense oligonucleotides and would continue to
grow. There is a possibility that difference in the growth-
inhibitory effect with PCNA-specific antisense oligomer in
each cell line may reflect differences in oligonucleotide uptake
and degradation in the cells. A single administration of
antisense oligomers showed only a weak effect (data not
shown) however when the medium containing antisense oli-
gomers was changed daily a remarkable growth-inhibitory
effect could be seen (see Figures 3 and 4). Thus, incorporated
antisense oligonucleotides may be degraded in the cells, and
the duration of the antiproliferative effect can be explained
by daily administration of fresh oligomer to the cells.
According to the previous study by Chiang et al. (1991),
the antisense-mediated effect depends on the secondary struc-
ture of the targeted messenger RNA, and a stable stem-loop
structure is desirable as the target site. It follows that
stability of DNA-RNA binding between oligomers and
target sequence of messenger RNA will change as a result of
a small shift of the target sequence. As shown in Table I, we
synthesised and tested three kinds of antisense oligomers.
Only antisense 1 (starting at base 1,447) showed growth-
inhibitory effect. Antisense 2 (starting at base 1,441) and
antisense 3 (starting at base 1,438) showed little effect. Differ-
ences in the extent of the growth-inhibitory effect in the three
kinds of antisense oligomers as shown in Table I may be
caused by this mechanism. Such differences in growth-
inhibitory effect caused by a small shift in the targeted
sequence was also shown in the previous report by Edith
Speir et al. (1992). It follows that it is necessary to choose the
desirable target sequence of messenger RNA according to its
secondary structure and to design structurally modified
oligonucleotides with greater stability and enhanced uptake
so that a large percentage of cancerous cells are inhibited.
Whether such molecules can be designed will have an impact
on the practicality of using antisense technology in clinical
situations. In addition, we found that PCNA-specific
antisense oligonucleotides inhibited proliferation of normal
fibroblasts to some extent, and so we must design administra-
tion routes or methods to minimise the effect on normal
cells.
We are now working to clarify whether or not the anti-
proliferative effect of this PCNA-specific antisense oligo-
nucleotide is specific to gastric cancer cells. According to our
preliminary experiments, PCNA-specific antisense oligo-
nucleotides show the same effect in other types ofcancer cells
as well as in gastric cancer cells (unpublished data). So this
effect may not be specific to gastric cancer cell lines.
Others have previously proposed that the inhibition of
cancer cells by antisense nucleic acids has important implica-
tions for the development of new cancer therapies (Cala-
bretta, 1991). Our results coincide with the observation that
antisense oligonucleotides can be given without any non-
specific toxicity (Agrawal et al., 1991). Further research will
focus on the potential for in vitro effectiveness as well as
clarifying the mechanism of action.
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